Skip to main content

Table 3 Dossier evidence use according to evidence characteristics

From: A study of the value of requesting information from drug manufacturers for systematic reviews; 9 years of experience from the drug effectiveness review project

 

Total included studies

Used qualitatively

Used in MA

Fills a gap

Confirms findings

Changes conclusion

All dossier evidence

160

142 (89%)

26 (16%)

72 (45%)

66 (41%)

67 (42%)

Unique studies

123

105 (85%)

24 (20%)

57 (46%)

47 (38%)

56 (46%)

Supplemental evidence

37

36 (97%)

2 (5%)

15 (41%)

19 (51%)

9 (24%)

By study design

 Head to head trial

41

32 (78%)

9 (22%)

18 (44%)

15 (37%)

21 (13%)

 Placebo-controlled trial

46

39 (85%)

10 (22%)

23 (50%)

21 (46%)

21 (46%)

 Observational study

28

27 (96%)

0

13 (46%)

5 (18%)

9 (32%)

Publication status

 Published (all)

95

81 (85%)

18 (19%)

43 (45%)

43 (45%)

37 (39%)

 Unpublished (all)

65

58 (89%)

8 (12%)

29 (45%)

23 (35%)

29 (45%)

 Unpublished unique studies

46

39 (85%)

8 (17%)

22 (48%)

14 (30%)

25 (54%)

 Unpublished supplemental

19

19 (100%)

0

7 (37%)

9 (47%)

4 (21%)

 Subgroup evidence

26

25 (96%)

3 (12%)

15 (58%)

9 (35%)

12 (46%)

DERP phase

 DERP II

68

62 (91%)

13 (19%)

22 (32%)

32 (47%)

16 (24%)

 DERP III

50

44 (88%)

7 (14%)

28 (56%)

19 (38%)

29 (58%)

 DERP IV

42

35 (83%)

6 (14%)

22 (52%)

15 (36%)

21 (50%)

Publication status by DERP phase

 Published

95

     

 DERP II

55

50 (91%)

9 (16%)

21 (38%)

24 (44%)

15 (27%)

 DERP III

17

14 (82%)

3 (18%)

8 (47%)

9 (53%)

7 (41%)

 DERP IV

23

17 (74%)

6 (26%)

14 (61%)

10 (43%)

15 (65%)

Unpublished

65

     

 DERP II

13

9 (69%)

4 (31%)

1 (8%)

8 (62%)

1 (8%)

 DERP III

33

30 (91%)

4 (12%)

20 (61%)

10 (30%)

22 (67%)

 DERP IV

19

19 (100%)

0

8 (42%)

5 (26%)

6 (32%)

Report type

160

     

 Original

48

39 (81%)

15 (31%)

19 (40%)

29 (60%)

23 (48%)

 Update

112

100 (89%)

11 (10%)

53 (47%)

37 (33%)

43 (38%)